2022
Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody‐associated disease
Li E, Zheng Y, Cai M, Lai Q, Fang G, Du B, Shen C, Zhang Y, Wu L, Ding M. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody‐associated disease. Epilepsia 2022, 63: 2173-2191. PMID: 35652436, DOI: 10.1111/epi.17315.Peer-Reviewed Original ResearchConceptsMyelin oligodendrocyte glycoprotein antibody-associated diseaseAquaporin-4 antibody-positive neuromyelitis optica spectrum disorderNeuromyelitis optica spectrum disorderAntibody-associated diseaseMultiple sclerosisCentral nervous system inflammatory demyelinating diseaseAutoimmune-associated epilepsyCerebral cortical encephalitisConcomitant systemic infectionPresence of status epilepticusAcute disseminated encephalomyelitisInflammatory demyelinating diseaseSecondary to inflammationAcute symptomatic seizuresDrug-drug interactionsAQP4-NMOSDCortical encephalitisMultiple relapsesDisseminated encephalomyelitisImpact of treatmentStatus epilepticusDisease activitySymptomatic seizuresAntiseizure medicationsInflammatory mechanisms
2020
HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window
Zhao J, Zheng Y, Liu K, Chen J, Lai N, Fei F, Shi J, Xu C, Wang S, Nishibori M, Wang Y, Chen Z. HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window. Neurotherapeutics 2020, 17: 710-721. PMID: 31802434, PMCID: PMC7283397, DOI: 10.1007/s13311-019-00815-3.Peer-Reviewed Original ResearchConceptsHigh mobility group box 1Anti-HMGB1 mAbStatus epilepticusTherapeutic targetLife-threatening neurological emergencyToll-like receptor 4 (TLR4)-dependent pathwayAnti-HMGB1 monoclonal antibodyNeutralization of HMGB1Plasma HMGB1 levelsMobility group box 1Severity of seizure activityExogenous high mobility group box 1Incidence of SENonrefractory SEHMGB1 levelsPredictive biomarkersTherapeutic responseNeurological emergencyTherapeutic windowBox 1Seizure activityMonoclonal antibodiesPharmacological therapeuticsSE periodEpilepticus